GET DAILY SIGNALSPharvaris N.V. (PHVS): An Oral Approach to Treating Hereditary Angioedema
Key Takeaways
- PHVS is the Nasdaq ticker for Pharvaris N.V., a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema (HAE) and other bradykinin-mediated diseases.
- The company's lead drug candidate is deucrictibant, an oral small-molecule bradykinin B2-receptor antagonist being developed in two formulations for on-demand treatment and preventive (prophylactic) use.
- Pharvaris was incorporated in 2015, is organized under Dutch law, and is headquartered in Zug, Switzerland.
- As a pre-revenue, late-stage developer, the company's value is tied to clinical trial results and regulatory approvals rather than product sales.
- Its oral approach targets an unmet need in HAE, where many existing treatments are administered by injection or infusion.
Getting to Know Pharvaris
Pharvaris N.V. is a late-stage biopharmaceutical company focused on rare diseases, particularly hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling attacks in areas such as the face, limbs, airways, and abdomen. I follow PHVS because the company is attempting to deliver a new oral treatment option in a therapeutic area that has historically relied on injectable or infused medicines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Understanding the Business Model
Pharvaris was founded in 2015 by executives with prior experience in the HAE field and is incorporated as a Dutch public limited company (the "N.V." in its name), with its headquarters in Zug, Switzerland. The company completed its initial public offering on Nasdaq in early 2021. In my view, its development-stage profile is typical for this sector.
The company's business model is typical of a development-stage biotechnology firm: it advances drug candidates through clinical trials toward regulatory approval and eventual commercialization. Its lead candidate, deucrictibant, is an orally available small molecule that blocks the bradykinin B2 receptor, a key pathway behind the swelling attacks seen in HAE. Pharvaris is developing deucrictibant in two oral formulations:
- An extended-release tablet, intended for prophylaxis — preventing HAE attacks before they occur.
- An immediate-release capsule/softgel, intended for on-demand treatment of attacks once they begin.
Because the company has not yet received marketing approval, it generates no product revenue. Its financial profile is defined by research and development spending, operating losses, and a cash position built from equity financings rather than sales. Deucrictibant has received orphan drug designation in the United States, the European Union, and Switzerland, a status intended to support development of treatments for rare diseases. From what I see, this positions the asset for potential expedited review paths.
Competitive Landscape in HAE
Pharvaris operates in a specialized but competitive rare-disease market. HAE is already served by several approved therapies, including injectable and infused products from larger pharmaceutical companies, as well as an oral prophylactic treatment. Pharvaris differentiates itself by pursuing a single oral molecule that could address both on-demand and preventive settings — a convenience advantage relative to therapies that must be injected. I reviewed sector patterns with Tickeron’s AI Pattern Search Engine to confirm the positioning.
The company's late-stage development program has included Phase 3 studies for both the treatment and prevention of HAE attacks, and regulatory applications for deucrictibant's immediate-release formulation have been submitted for review in the United States and Europe. Among its direct competitors is BCRX (BioCryst Pharmaceuticals), which markets an oral prophylactic HAE therapy.
What Draws Investors to PHVS
Investor attention centers on Pharvaris's potential to shift the standard of care in HAE toward convenient oral therapy. Key long-term drivers include the size of the unmet need, the possibility of a dual on-demand and prophylactic label, and the company's experienced management team with prior success in the HAE space. As clinical data read out and regulatory decisions approach, these milestones tend to drive meaningful re-evaluations of the company's outlook. This is important because successful approvals could reshape treatment preferences.
Risks and Important Considerations
Investing in PHVS carries substantial risk. The company has no approved products or product revenue and has consistently reported net losses as it funds clinical development. Its value is highly concentrated in a single asset, deucrictibant, meaning setbacks in clinical trials, manufacturing, or regulatory review could have an outsized impact. The HAE market is also competitive, and Pharvaris must demonstrate that its oral approach offers meaningful advantages over established therapies. Because it is a pre-revenue company, it may need additional capital in the future, which could dilute existing shareholders. I’m watching this closely given the binary nature of clinical outcomes.
Exploring Opportunities with Tickeron’s AI Screener
Tickeron’s AI Screener helps me identify stocks that fit specific criteria by combining technical indicators, fundamentals, and AI signals. I use it regularly to screen for biotech names with similar development profiles and refine ideas before digging deeper into clinical timelines.
Wrapping Up
Pharvaris N.V. is a focused, late-stage biotechnology company pursuing an oral treatment for hereditary angioedema, a rare and potentially serious condition. Its single-candidate strategy and oral convenience angle make it a distinctive participant in the HAE market, while its pre-revenue status and development-stage risks make it a higher-volatility holding. The company's relevance for investors will continue to hinge on clinical outcomes, regulatory decisions, and its ability to eventually commercialize deucrictibant.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PHVS in upward trend: price rose above 50-day moving average on November 06, 2026
PHVS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PHVS as a result. In 98 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 49 of 55 cases over the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for PHVS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 192 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for PHVS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where PHVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for PHVS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.026) is normal, around the industry mean (3.498). P/E Ratio (-13.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement